Tower Bridge Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Tower Bridge Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-617	Closed	-$594K	–	196
2024 Q1	$594K	Hold	617	–	–	0.06%	146
2023 Q4	$542K	Hold	617	–	–	0.05%	161
2023 Q3	$508K	Hold	617	–	–	0.05%	158
2023 Q2	$443K	Buy	617 +100	+19%	+$77.1K	0.04%	156
2023 Q1	$425K	Buy	517 +200	+63%	+$151K	0.03%	181
2022 Q4	$229K	Hold	317	–	–	0.02%	223
2022 Q3	$218K	Buy	+317	New	+$200K	0.02%	217
2022 Q2	–	Sell	-317	Closed	-$221K	–	256
2022 Q1	$221K	Hold	317	–	–	0.01%	242
2021 Q4	$200K	Buy	+317	New	+$195K	0.01%	253

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Tower Bridge Advisors's REGN Position: Q2 2024 in Review

Tower Bridge Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 617 shares — an estimated $594K sold.

Tower Bridge Advisors first reported a position in REGN in Q4 2021 and held it in 9 quarters. The position peaked at $594K in Q1 2024. 1,334 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

Tower Bridge Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Tower Bridge Advisors sold 617 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $594K.
Tower Bridge Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 9 quarters.
Tower Bridge Advisors's Regeneron Pharmaceuticals position peaked at $594K in Q1 2024.
1,334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on Tower Bridge Advisors's 13F filing for Q2 2024, filed 24 Jul 2024.